in patient five. The three patients who did not undergo CRS eventually underwent CRS for management of persistent re current disease. The detailed summary of the patients' clinical pathway is presented in Table 1 .
In total, eight cytoreductive surgeries using peritonectomy procedures were performed in five patients, of which one pa tient received intraoperative hyperthermic intraperitoneal cis platin for 90 minutes at 42 o C. There was no inhospitalization treatment related mortality. The median length of operation was 5.3 hours (range, 3.3 to 10 hours). The median length of stay in hospital was 10 days (range, 7 to 87 days). Patients one and two recovered uneventfully. Severe postoperative compli cations as graded according to the National Cancer Institute's Common Toxicity Criteria occurred in patient three at the time of peritonectomy for the fourth recurrence, in patient four at the time of peritonectomy for the second recurrence, and in patient five at the time of first peritonectomy for treatment for third recurrence. Patient three had a 24 day hospital stay after suffering from a grade III postoperative complication, requir ing percutaneous drainage of a retroperitoneal abscess under radiological guidance. Patient four remained hospitalized for 87 days following grade IV postoperative complications with re nal impairment secondary to intraperitoneal cisplatin, right pleu ral effusion requiring chest drain placement, rectocysto vaginal fistula and sepsis. Patient five had a 12 day hospital stay after suffering from grade III postoperative complication, re quiring percutaneous drainage of a right upper quadrant collection.
Following CRS, patient one, four and five are disease free. However, disease recurrence was seen in patient two and three in whom repeat peritonectomy was performed. 216 www.ejgo.org recurrences 30 months after first peritonectomy, where a re peat peritonectomy was performed. A further diseasefree in terval of 29 months was achieved before the development of a nodal recurrence which was treated with debulking surgery where lymphadenectomy was performed. Subsequently, the patient developed peritoneal recurrence 30 months later and underwent a third repeat peritonectomy. With a median fol lowup of 38 months after the first peritonectomy treatment, all five patients are still alive 10 to 95 months after treatment with no evidence of disease. Disseminated peritoneal metastasis of GCT is characterized intraoperatively by the extensive presence of macroscopic whitish tumor nodules of variable sizes and consistency that may coalesce to form plaques or masses within the abdomi nopelvic cavity. These nodules and plaques may also layer out and line the entire peritoneal surface. This phenomenon in recurrent GCT has been previously described [3] . It occurs as a result of direct serosal invasion, perforation or rupture of the primary ovarian tumor. It may also be related to iatrogenic mechanisms during invasive procedures such as fineneedle cytology or spillage of tumor content during surgical inter vention. As with other forms of malignancies that disseminate extensively on the peritoneal surface, such as colon cancer, epithelial ovarian cancer and peritoneal mesothelioma, perito neal metastases has traditionally been regarded incurable and is associated with a poor prognosis. Patients with advanced ovarian cancer have a 5year survival of less than 25% [4] . In a Korean multicenter study of 113 patients with GCT, FIGO stage predicted for recurrence in patients after initial treatment [5] .
Surgical treatment of peritoneal metastases from recurrent GCT is unduly challenging. Conventional debulking surgery is insufficient in attaining complete cytoreduction. Peritonec tomy procedures, as described by Sugarbaker [6] , is a surgical procedure that involves the removal of the diseased perito neum as a means of achieving complete cytoreduction. It has brought about a new paradigm into the treatment of perito neal metastases. We demonstrate the feasibility of employing peritonectomy procedures to achieve complete cytoreduc tion in the five patients and have demonstrated prolonged diseasefree survival ranging from 10 to 95 months. In patients who develop recurrence, repeat peritonectomy is a reason able option, as shown in patient three, where a diseasefree interval of 29 months was achieved after the second perito nectomy. This may be a reflection of the indolent biology of this disease where a longterm survival can be achieved if complete cytoreduction is performed. Nonetheless, severe postoperative complications may occur as a result of the pro cess of aggressive cytoreduction. This must be balanced with any hope of longterm survival this treatment may offer.
Various other treatment modalities are employed in the treatment of recurrent disease; chemotherapy, radiotherapy and hormonal therapy. The common chemotherapy regime used in this setting is a combination of bleomycin, etoposide, and cisplatin. Although, the response rate to this regimen ranges between 51 to 90%, the effectiveness of this treatment remains poor with a median diseasefree survival of only 14 to 24 months [7, 8] . Outcomes of radiotherapy and hormonal therapy are also poor, with response rates being 43 and 40% respectively. Overall median survival following radiotherapy treatment is 156 months in responders and 12 months in nonresponders [9] . Patients treated with hormonal therapy develop progressive disease after 8 months [10] . Therefore, the only available effective treatment that has demonstrated a prolonged survival is surgery [1, 3] .
From our experience, nonsurgical management of recurrent GCT is only employed in the setting of unresectable disease. In selected patients who are suitable to undergo surgery, max imal cytoreduction with a curative intent that includes tumor resection, retroperitoneal lymphadenectomy and peritonec tomy should be considered. Our report is the first to describe the use of peritonectomy procedures to achieve maximal cytoreduction in patients with recurrent GCT, demon strating the feasibility and safety of this treatment option. We have not begun routinely administering intraoperative hyperthermic intraperitoneal chemotherapy for patients with peritoneal metastases from GCT; however it may be worth considering given the 51 to 90% response rate observed when adminis tered intravenously for which may potentially be higher when administered intraperitoneally. Following evidence from the literature that suggests that maximal cytoreduction is an im portant aspect of treatment in recurrent GCT [1] , we have de scribed the use of peritonectomy to achieve complete cytore duction in patients with peritoneal metastases from recurrent GCT.
